Lonza and Innosieve Diagnostics Announce Exclusive Distribution Agreement for Rapid Bioburden Testing Technology

Cologne (DE) and Wageningen (NL) 04 June 2018 – Lonza Pharma & Biotech and Innosieve Diagnostics announced today an exclusive distribution agreement for rapid bioburden testing technology. This agreement expands Lonza’s extensive offering of endotoxin products, services and software and provides pharmaceutical testing professionals with a comprehensive set of quality control (QC) tools. Under the agreement, Lonza... Read more